Theriva Biologics, Inc.

TOVX XASE • PHARMACEUTICAL PREPARATIONS

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

10M

Short interest (Jul 15)

5.1%

Net Short (Jul 27 ): 0.1%

Borrow Fee

17.71%

↓ 11.0%

Available Shares

↑ 53.1%

Price Chart

Company Overview

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.

Company Info

Exchange: XASE

Industry: PHARMACEUTICAL PREPARATIONS

CIK: 0000894158

Asset Type: CS

Market Data

Market Cap: $10,229,475

Employees: 16

Status: Active

Short Interest

Current Borrow Fee 17.71%

Range: 17.71% - 17.71%

Available Shares 2M

Range: 2.1M - 2.7M

Recent Changes

Fee Change: ↓ 1.1%

Available Change: ↓ 0.0%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime